壬-3,8-二烯-2,5-二酮 | 81880-18-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 壬-3,8-二烯-2,5-二酮
• 英文名称: nona-3,8-diene-2,5-dione
• 英文别名: Nona-3,8-dien-2,5-dion
• CAS: 81880-18-4
• 化学式: C₉H₁₂O₂
• 分子量: 152.193
• InChiKey: ILCHOHPULDOEHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  壬-3,8-二烯-2,5-二酮 、 盐酸氨基脲 在 吡啶 、 乙醇 作用下， 生成 nona-3,8-diene-2,5-dione disemicarbazone
  参考文献：
  名称：

  Schechter; Green; La Forge, Journal of the American Chemical Society, 1949, vol. 71, p. 3168

  摘要：

  DOI：
• 作为产物：
  描述：

  3-hydroxy-8-nonene-2,5-dione 在 sodium acetate 、 乙酸酐 作用下， 生成 壬-3,8-二烯-2,5-二酮
  参考文献：
  名称：

  Schechter; Green; La Forge, Journal of the American Chemical Society, 1949, vol. 71, p. 3168

  摘要：

  DOI：

文献信息

• THIOL-ENE CURABLE COMPOSITION
  申请人：Showa Denko K.K.

  公开号：EP3798251A1

  公开（公告）日：2021-03-31

  To provide a thiol-ene curable composition which achieves both sufficient elongation properties and elasticity, and ensures the preservation stability of a formulation. The thiol-ene curable composition includes a compound (A) having an isocyanuric skeleton and at least two mercapto groups in one molecule, and at least one of a compound (B) including diallyl maleate and diallyl fumarate. The compound (A) is at least one selected from 1,3,5-tris(3-mercaptobutyryloxyethyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione, tris-[(3-mercaptopropionyloxy)-ethyl]-isocyanurate, and tris(mercaptopropyl)isocyanurate.

  提供一种硫醇-烯固化组合物，它既能获得足够的伸长性能和弹性，又能确保配方的保存稳定性。 该硫醇-烯固化组合物包括具有异氰尿酸骨架且一个分子中至少含有两个巯基的化合物 (A)，以及包括马来酸二烯丙基酯和富马酸二烯丙基酯在内的至少一种化合物 (B)。 化合物 (A) 至少选自 1,3,5-三(3-巯基丙酰氧基乙基)-1,3,5-三嗪-2,4,6(1H,3H,5H)-三酮、三[(3-巯基丙酰氧基)-乙基]-异氰脲酸酯和三(巯基丙基)异氰脲酸酯中的一种。
• Effects of 2% Ibopamine on Pupil, Refraction, Anterior Segment Anatomy and Intraocular Pressure
  作者：Giorgio Marchini、Silvia Babighian、Roberto Tosi、Sergio Perfetti、Luciano Bonomi

  DOI：10.1089/108076801750295254

  日期：2001.6

  The aim of the study was to determine the effects of a dopaminergic drug, 2% ibopamine, on the pupil, intraocular pressure and other ocular and ultrasound biometric variables.Thirty healthy subjects and 15 patients with primary open-angle glaucoma, aged from 40 to 78 years (mean age: 59.2 +/- 11), were included in two prospective open controlled trials. In the first, the mydriatic effect of 2% ibopamine and its inhibition and reversibility were evaluated in 15 healthy subjects using the alpha(1)-adrenergic drug, 0.5% dapiprazole. In the second, refraction, visual acuity, pupil diameter, intraocular pressure and 5 A-scan ultrasound biometric variables were evaluated in 15 healthy subjects and in 15 glaucoma patients.As early as forty min after administration of 2% ibopamine, a marked mydriatic ef feet (7.3 vs 3.9 mm; P < 0.0001), which was completely inhibited or reversed by 0.5% dapiprazole, was detected. The drug induced no changes in refraction, visual acuity or Ascan ultrasound biometric variables in any of the subjects examined. In healthy subjects, the intraocular pressure values were not changed to a statistically significant extent (13.8 vs 14.8 mm HE; P = 0.668), whereas a slight, though significant, hypertensive effect (24 vs 22.2 mm Hg, P = 0.002) was observed in the glaucoma patients.The study confirms the intense mydriatic effect of 2% ibopamine with no changes in refraction, visual acuity or A-scan ultrasound biometric variables, The drug has no effect on intraocular pressure in healthy subjects, but induces a significant hypertensive effect in patients with initial glaucoma. This characteristic could be used for early diagnosis of primary open-angle glaucoma.